Med onc at UW/SCCA/Fred Hutch focused on melanoma and RCC, interested in patient/caregiver QOL and all things immunotherapy. All opinions are my own.
Jun 7, 2021 • 4 tweets • 1 min read
My take on #ASCO21 plenary data on adjuvant pembrolizumab for #kidneycancer: Promising DFS results are a good start. It is not surprising that OS is immature. This could very well be the way we treat high-risk localized RCC pts post-nephrectomy in the future. 1/4
9% abs diff in 24 month DFS, corresponds to NNT of 10-11. For stage III melanoma (pembro vs placebo - KEYNOTE-054), abs diff in 24 month RFS was 15-20% depending on stage (NNT 5-6). This will be a nuanced decision in clinic with lots of personalized risk-benefit discussion. 2/4
Jun 7, 2021 • 11 tweets • 3 min read
With one day for the dust to settle, here are my thoughts on some of the #ASCO21#melanoma data. 1) It is interesting to me that no adj PD-1 melanoma study has yet shown OS benefit vs comparator arm (CM238 - nivo vs ipi, S1404 - pembro vs HDI or ipi, KN054- pembro vs placebo).
Is this because more time in f/u is needed to see diffs emerge? Or does it suggest that PD-1 is equally effective regardless of disease setting (adj vs metastatic) and that enough pts with metastatic melanoma have durable long-term control on PD-1 to explain lack of OS benefit?
